We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Rentschler Biopharma Contributes to Nearly 25% of FDA Approved Biopharmaceuticals in 2023

A scientist holding up a small vial.
Credit: Diane Serik / Unsplash.
Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute

In 2023, the U.S. Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER) approved 55 new drugs, 17 of which were biopharmaceuticals. Rentschler Biopharma SE, a leading contract development and manufacturing organization (CDMO) for biopharmaceuticals, including advanced therapy medicinal products (ATMPs), contributed to four, which equals nearly 25%, of these biopharmaceuticals.  


Federico Pollano, Senior Vice President Business Development at Rentschler Biopharma, commented: “Guiding a promising therapy from its initial clinical trials to commercialization is a demanding endeavor that spans numerous years of development efforts. We provide clients with world-class solutions along the entire biopharmaceutical value chain from bioprocess development to manufacturing and regulatory support. These recent approvals illustrate our capability to support our client partners through this entire and challenging process, emphasizing the importance of our expertise and flexibility to match unique client needs.”

Want more breaking news?

Subscribe to Technology Networks’ daily newsletter, delivering breaking science news straight to your inbox every day.

Subscribe for FREE

Currently, Rentschler Biopharma is manufacturing a total of eight market approved biopharmaceuticals for its clients, including complex formats such as bispecific antibodies, as well as recombinant enzymes. Rentschler Biopharma’s involvement in successfully bringing these therapeutics to the market underpins the company’s strategic role in developing innovative treatments for patients suffering from cancer, autoimmune disorders, as well as rare diseases. For the four newly approved products, Rentschler Biopharma provided support with integrated capabilities, including consulting, regulatory services, process development, technology transfer and manufacturing. These collaborations involved international clients, showcasing the company’s global reach and excellence across its manufacturing sites.


Benedikt von Braunmühl, CEO of Rentschler Biopharma, said: “At Rentschler Biopharma, we strive to create value sustainably, together with our client partners, for patients with serious and rare diseases worldwide. Market approved products truly serve those patients and their caregivers by bringing them new therapeutic options. I am very grateful and proud that our company continuously makes important contributions in the development and manufacturing of innovative biopharmaceuticals and in realizing our clients’ ideas. My sincere gratitude goes to our cross-site teams for their integral contributions to this significant milestone and for their dedication, which is reflected in every aspect of our work.”